Social Media Ideas for Emerging Therapy

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

Proposing the Synergy of Therapeutic Plasma Exchange and Partial Epigenetic Reprogramming

It seems a little early in the development of partial epigenetic reprogramming as a class of therapy to be thinking about which of the other approaches to aging it can best be comb...

Lycia’s Experimental Therapy Introduces a New Way to Treat Food Allergies

Lycia's experimental therapy removes IgE instead of blocking it and is expected to enter Phase 1 clinical testing soon. The post Lycia’s Experimental Therapy Introduces a New Way t...

Legend surges on early data for ‘in vivo’ lymphoma cell therapy

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like N...

BioTrinity 2026 Showcases Delivery Technologies and Promising Therapeutic Candidates

All the technologies featured at BioTrinity 2026 have the goal of addressing unmet needs in areas like chronic wounds and ophthalmic diseases, and the associated companies highligh...

From Discovery to Development in Emerging Modalities

ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities a...

Novel Therapeutic Modalities Target the Undruggable

Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable a...

Bloodlines Series: CAR T-cell Therapy Shows Promise for Smoldering Myeloma

An immunotherapy typically used in advanced stages of multiple myeloma may be effective against an early form of the disease known as smoldering myeloma—offering a potential new op...

Preparing Benefits For the Next Wave: Gene Therapy Medications

The rise of metabolic gene therapies represents a critical juncture for benefits management. These treatments offer genuine hope for patients with serious conditions, but they also...

China Sets Framework for Advanced Therapeutic Development

China’s Order 818 signals the country’s intent to accelerate local innovation and standardize the drug development environment, thereby becoming a more important player in advanced...

Relay drug shows early promise against rare blood vessel diseases

While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments...

<![CDATA[The Future for Disease Modifying Therapies for Lysosomal Disorders]]>

Ethyreal starts up with $101M and takes aim at a pair of immune diseases

The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.

EMA Accepts Otarmeni Gene Therapy for OTOF-Related Hearing Loss for Review

If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.

Gene therapy is changing how we treat disease

HN Summary • Gene therapy is shifting medicine from treating symptoms to targeting disease at its genetic source, offering new hope for conditions such as Huntington’s disease, sic...

Immunotherapy combination may improve liver cancer outcomes

CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to resu...

Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease

“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development at Fate Therapeutics, told Fierce.

Breakthrough in Cell Therapy Enhances Treatment for Advanced Liver Disease

A pioneering advancement in the treatment of advanced liver disease has emerged from the University of Edinburgh, offering fresh hope to patients who face dire prognoses due to cir...

Novel Epigenetic Therapy Targets Treatment-Resistant and TP53-Mutant AML

The results of a preclinical study across multiple models of acute myeloid leukemia found that the investigational hypomethylating agent, NTX-301 remained effective in treatment-re...

How NEC's AI and oral delivery system are redefining personalized cancer therapy

Neoantigen-based therapies are considered one of the most promising approaches in modern immuno-oncology. One challenge continues to limit the field: accurately identifying which n...

FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development

Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.

First-in-the-world gene therapy delivers missing gene directly to infant's brain

An 8-month-old infant with severe genetic epilepsy has become the first patient in the world to receive an experimental gene replacement therapy designed to restore the function of...

‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEs

When it comes to turning T-cell therapies toward autoimmune diseases, CAR-Ts have been leading the way. But another red-hot modality is also beginning to show potential in the clin...

Orca Bio Cell Therapy Gets Landmark FDA Nod for New Kind of Living Medicine

FDA approval of Orca Bio’s Tregzi makes it the first cell therapy based on regulatory T cells, or Tregs. Clinical trial results showed reduced risk of graft-versus-host disease, a...